Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy ± chemotherapy in the BC2001 phase III randomised controlled trial
European Urology Mar 08, 2020
Huddart RA, Hall E, Lewis R, et al. - Researchers examined a total of 458 UK individuals with T2-T4a N0 M0 transitional cell carcinoma of the bladder to ascertain the effect of treatment on the health-related quality of life (HRQoL) of BC2001 individuals. Individuals were assigned randomly to the chemotherapy comparison (radiotherapy, 178, or chemoradiotherapy, 182); and/or to the radiotherapy comparison (standard, 108, or reduced high-dose volume radiotherapy, 111). The results of this study indicated that immediately following (chemo)radiotherapy, a significant proportion of patients report declines in HRQoL, which improves to baseline after 6 months. The study found that two-thirds of individuals report stable or increased HRQoL on long-term follow-up. In HRQoL, there is no indication of impairment occurring from the addition of chemotherapy.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins